AtheroGenics To Host Conference Call And Webcast To Discuss ARISE Phase III Clinical Trial Results
AtheroGenics, Inc. (NasdaqGM:AGIX - News), a pharmaceutical company focused on the treatment of chronic inflammatory diseases, today announced that it will host a conference call and webcast to discuss key clinical findings from the ARISE Phase III trial of AGI-1067 on Tuesday, March 27, 2007, at 4:00 PM EDT.
ARISE study results are scheduled to be presented by Jean-Claude Tardif, M.D., Director of Research; Professor of Medicine, Montreal Heart Institute; and Marc Pfeffer, M.D., Ph.D., Professor of Medicine, Harvard Medical School; Senior Physician in Cardiology at Brigham and Women’s Hospital, at the Late Breaking Clinical Trials session (Room Hall A) at the American College of Cardiology (ACC) Annual Scientific Sessions in New Orleans on Tuesday, March 27 at 9:35 AM CDT.
Webcast and Conference Call Details
Date: March 27, 2007
Time: 4:00 PM EDT (3:00 PM CDT)
Dial in: Domestic - 877-407-8031
International - 201-689-8031
Replay Dial in: Domestic - 877-660-6853
International - 201-612-7415
Replay Codes: Account # 286
Conference ID# 235811
This news content was configured by WebWire editorial staff. Linking is permitted.
News Release Distribution and Press Release Distribution Services Provided by WebWire.